References
- Merck Index, 10th edn., M Windholz. Merck & Co, Rahway, NJ 1983; 707
- Merck Index, 10th edn., M Windholz. Merck & Co, Rahway, NJ 1983; 1216
- Merck Index, 10th edn., M Windholz. Merck & Co, Rahway, NJ 1983; 930
- Merck Index, 10th edn., M Windholz. Merck & Co, Rahway, NJ 1983; 1067
- Merck Index, 10th edn., M Windholz. Merck & Co, Rahway, NJ 1983; 828
- Merck Index, 10th edn., M Windholz. Merck & Co, Rahway, NJ 1983; 766
- Goodman, Gilman. Textbook of Pharmacology 7th edn. Macmillan, NY, 628–39
- Sourkes T L. Toxicology of Serotonin precursors. Adv Biol Psych 1983; 10: 160–75
- Schneider-Helmert D, Spinweber C L. Evaluation of L-tryptophan for treatment of insomnia: a review. Naval Health Res Cntr, Nav Med Res Develop Com. January, 1984, Report 84–4
- Sicuteri F, Anselmi B, Del Berne E, Galli P. 5-hydroxytryptamine and pain modulation in man: a clinical pharmacological approach with tryptophan and parachlorophenylalanine. Acta Vit Enzymol (Milano) 1975; 29: 66
- Sternback R A, Janowsky D S, Huey L Y, . Effect of altering brain serotonin activity on human chronic pain. Advances in Pain Research and Therapy, Vol 1, J Bonica, D Albefessard, et al. Raven Press, New York 1976
- Kangasniemi P, Falck B, Langvik V-A, Hyppa M T. L-tryptophan treatment in migraine. Headache 1978; 18: 161–6
- Thompson J, Rankin H, Ashcroft G W, et al. The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline, with placebo. Psychol Med 1982; 741–51
- Facts and Comparisons. 1990
- Personal Communication. CDC Epidemiology Branch. 1991
- Markey S. Personal Communication. 1990
- Hertzman P A, Blevins W L, Mayer J, et al. Association of the Eosinophilia-myalgia syndrome with the ingestion of Tryptophan. N Eng J Med 1990; 322: 869–73
- Silver R M, Heyes M P, Maize J C, et al. Seleroderma, fasciitis, and eosinophilia associated with the ingestion of Tryptophan. N Eng J Med 1990; 322: 874–81
- Jaffe R M. Eosinophilia-myalgia syndrome caused by contaminated tryptophan. Intl J Biosoc Med Res 1989; 11: 181–4
- Caston J C, Rofs J B, Forgarty C M, et al. Treatment of refractory eosinophilia-myalgia syndrome associated with the ingestion of L-tryptophan containing products. Adv Therapy 1990; 7: 1–23
- Mayeno A N, et al. Characterization of ‘peak E’, a novel amino acid associated with eosinophilia-myalgia syndrome. Science 1990; 250: 1707–8
- Sakimoto K. The cause of eosinophilia-myalgia syndrome associated with tryptophan use. N Eng J Med 1990; 323: 992–3
- Crofford L J, Rader J I, Dalakas M C, et al. L-Tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. J Clin Invest 1990; 86: 1757–63
- Belongia E A, Hedberg C W, Gleich G J, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Eng J Med 1990; 323: 357–65
- Slutsker L, et al. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA 1990; 264: 213–7
- Osterholme, et al. Food Chem News 1990; 11 June: 25
- New Scientist 1982; 8 April: 85
- Jaffe R. Improve immune function using specific nutrient supplementation and ELISA/ACT “Immunologic Fingerprint” to detect late phase responses ex Vivo. J Am Coll Nut 1989; 8: 142